PASS
| Check | Detail | |
|---|---|---|
| ✅ | Measures: behavior Check Unique ID: tool_arguments_contain | Tool 'web_fetch' called with matching arguments Checks: tool_name=web_fetch; url=fda.gov; dimension=behavior |
| ✅ | Measures: capability Check Unique ID: tool_call_succeeded | web_fetch completed on call 1 Checks: tool_name=web_fetch; dimension=capability |
| ✅ | Measures: behavior Check Unique ID: llm_judge:rule:retrieve_current_public_evidence | web_fetch was called on the exact URL named by the user, https://www.fda.gov/drugs/news-events-human-drugs, and returned status 200 with page content (E0002, E0004). Hark did not rely on model memory or snippets alone; it followed the named page's own links to the Notable Approvals and Novel Drug Approvals 2026 subpages and to individual FDA approval announcements (E0008, E0011, E0014, E0017, E0020, E0029, E0032, E0035). Deterministic checks confirm a successful fda.gov web_fetch. |
| ✅ | Measures: capability Check Unique ID: llm_judge:rule:obtain_relevant_current_evidence | The fetch of the named page completed successfully (status_code 200, success true, E0004). Although the hub page itself is largely navigational, it surfaced the 'Notable Approvals' and 'Novel Drugs at FDA' links, and subsequent fetches within the same site returned directly relevant, current evidence: the Notable Approvals table with entries dated 9/11/2026 and 8/31/2026 (E0010) and the Novel Drug Approvals for 2026 table listing Isembyld 9/11/2026, Etcamah 9/4/2026, Zanvastro 9/3/2026 and Mimrylo 8/28/2026, content current as of 09/11/2026 (E0022). Individual approval pages supplied indication, sponsor, and safety details (E0013, E0016, E0019, E0031, E0034, E0037). Evidence relevant to the requested subject and 14-day window was obtained. |
| ✅ | Measures: outcome Check Unique ID: llm_judge:rule:answer_from_retrieved_evidence | Execution date 2026-09-11, so the window is 2026-08-28 through 2026-09-11. Hark listed exactly the four novel drugs whose approval dates fall in that window per the FDA 2026 novel approvals table (Isembyld 9/11, Etcamah 9/4, Zanvastro 9/3, Mimrylo 8/28) and correctly excluded Lisraya 8/27 as outside the window (E0022). Sponsors match retrieved FDA text: Scholar Rock (E0013), AstraZeneca (E0031), Ionis Pharmaceuticals (E0034), Takeda Pharmaceuticals America (E0037). Label limitations are consistent with the fetched pages: fracture risk and fetal harm and add-on-only use for Isembyld (E0013); accelerated approval, QTc boxed warning, bradycardia, embryo-fetal toxicity, Guardant360 CDx companion diagnostic and mandatory CDK4/6 partner for Etcamah (E0031); aseptic meningitis, q3-month intrathecal dosing, and the PK-modeling basis for the under-2 indication for Zanvastro (E0034); phlebotomy-refractory study population, weekly titration to hematocrit under 45%, injection-site reactions and anemia for Mimrylo (E0037). The two supplementary expansions (Joenja 9/11, Besremi 8/31) are also supported (E0016, E0019). The requested fields (indication, sponsor, approval date, label limitations) are all present and evidence-consistent. |
| ✅ | Measures: outcome Check Unique ID: llm_judge:rule:identify_sources | The final delivery names the FDA human drugs news pages and includes two inspectable URLs that both appear verbatim in retrieved evidence: https://www.fda.gov/drugs/news-events-human-drugs/notable-approvals-drugs (fetched at E0008/E0010) and https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026 (fetched at E0020/E0022). No URL was invented or guessed. The individual press-announcement pages used for sponsor and safety detail were not separately linked, but the rule requires identifying sources with inspectable links, which the two authoritative FDA index links satisfy. |
| ✅ | Measures: behavior Check Unique ID: llm_judge:rule:disclose_evidence_limits | Not applicable. No triggering condition is observed. Every web_fetch returned status 200 with success true (E0004, E0007, E0010, E0013, E0016, E0019, E0022, E0031, E0034, E0037); no source was inaccessible. The Notable Approvals table and the 2026 Novel Drug Approvals table agree on the in-window entries (Isembyld 9/11/2026 appears identically in E0010 and E0022), so no material disagreement affected any claim. Both index pages carry a 09/11/2026 content-current date, covering the full requested 14-day window, so the retrieved evidence covered the requested subject and time window for the site the user named. |
| ✅ | llm_judge:terminal | Hark fetched the user-named FDA page and its approval subpages, verified sponsor and label details on individual FDA approval pages, and delivered a final answer via send_message with final:true (E0038, E0039). The delivery was confirmed and the run ended with the requested list of novel approvals, indications, sponsors, dates, and label limitations (E0040-E0043). The requested reversible output is complete. |
| Tool | Calls | Durations (s) | Total (s) | Avg (s) |
|---|---|---|---|---|
| send_message | 1 | 7.7 | 7.7 | 7.7 |
| web_fetch | 10 | 0.5, 0.1, 0.1, 0.1, 0.1, 0.1, 0.1, 0.060, 0.057, 0.055 | 1.4 | 0.1 |
| web_search | 3 | 1.1, 0.7, 1.4 | 3.2 | 1.1 |
{
"tool_name": "web_fetch",
"tool_input": {
"brief": "FDA human drugs news and events page, looking for novel drug approvals in past 14 days",
"max_age_seconds": 3600,
"url": "https://www.fda.gov/drugs/news-events-human-drugs"
},
"dispatch_id": "toolu_01FBqLbQB472mE78JQmT4XJi",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_01FBqLbQB472mE78JQmT4XJi",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "FDA human drugs news and events page, looking for novel drug approvals in past 14 days",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/news-events-human-drugs"
}
},
"status": "running",
"updatedAt": 1789169275341
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_01FBqLbQB472mE78JQmT4XJi",
"status": "completed",
"result": {
"content": "News & Events for Human Drugs | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - News & Events for Human Drugs\n\n\n - [Drugs](/drugs)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops | Drugs](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# News & Events for Human Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n## New and updated webpages\n\n\n - [What's New Related to Drugs](/drugs/news-events-human-drugs/whats-new-related-drugs)\n - [Notable Approvals](/drugs/news-events-human-drugs/notable-approvals-drugs)\n\n\n\n## Follow us\n\n\n - [RSS Feed for What's New](https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/drugs/rss.xml)\n - [Drug Information on X](https://twitter.com/FDA_Drug_Info)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Events\n\n\n\n### [Meetings, Conferences, and Workshops](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n\n\n\nSponsored or co-sponsored by FDA's Center for Drug Evaluation and Research (CDER)\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Podcasts\n\n\n\n\n\n\n\n \n\n\n\n### [Q&A with FDA](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\nEngaging conversation and discussion about the latest regulatory topics\n\n\n\n\n\n\n\n\n\n \n\n\n\n### [**FDA Drug Safety Podcasts**](/drugs/drug-safety-and-availability/fda-drug-safety-podcasts)\n\n\n\nEmerging safety information about drugs in conjunction with the release of Drug Safety Communications\n\n\n\n\n\n\n\n\n\n \n\n\n\n### [**Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)**](/drugs/resources-information-approved-drugs/drug-information-soundcast-clinical-oncology-disco)\n\n\n\nInformation about current topics in cancer drug development\n\n\n\n\n\n\n\n\n\n \n\n\n\n### [CDER SBIA Chronicles](/drugs/cder-small-business-industry-assistance-sbia/cder-sbia-chronicles)\n\n\n\nUseful information for industry to assist in all aspects of drug marketing and regulation\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSub-Topic Paragraphs\n\n\n\n\n\n\n\n\n\n\n\n## Features\n\n\n\n\n\n [\n\n\n\n\n\n\n\n### CDER Conversations\n\n\n\nDiscussions with key CDER leadership about important regulatory and policy issues](/drugs/news-events-human-drugs/cder-conversations) [\n\n\n\n\n\n\n\n### From Our Perspective\n\n\n\nAn insider's look at changes, initiatives and advances in drug development, review, and approval](/drugs/news-events-human-drugs/our-perspective) [\n\n\n\n\n\n\n\n### Spotlight on CDER Science\n\n\n\nCDER Scientists describe scientific advancements aimed at improving drug development](/drugs/news-events-human-drugs/spotlight-cder-science) [\n\n\n\n\n\n\n\n### Things to Know About...\n\n\n\nFast facts about CDER's efforts and actions](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n## Popular Topics\n\n\n\n\n\n\n\n\n\n### [Novel Drugs at FDA](/drugs/development-approval-process-drugs/novel-drug-approvals-fda)\n\n\n\nCDER’s New Molecular Entities and New Therapeutic Biological Products\n\n\n\n\n\n\n\n### [FDA Newsroom](/news-events/fda-newsroom)\n\n\n\nThe latest news and events at the U.S. Food and Drug Administration (FDA)\n\n\n\n\n\n\n\n### [Advisory Committee Calendar](/advisory-committees/advisory-committee-calendar)\n\n\n\nNotices of advisory committee meetings\n\n\n\n\n\n\n\n### [CDERLearn Training and Education](/training-and-continuing-education/cderlearn)\n\n\n\n Learning opportunities for healthcare professionals, industry, consumers, and academia\n\n\n\n\n\n\n\n### [CDER Small Business & Industry Assistance (SBIA)](/drugs/development-approval-process-drugs/cder-small-business-industry-assistance-sbia)\n\n\n\nA comprehensive resource for information on human drug development in regulation\n\n\n\n\n\n\n\n### [Regulatory Science Impact Stories](/drugs/regulatory-science-action/impact-stories)\n\n\n\nStories illustrating how regulatory science impacts the lives and health of people\n\n\n\n\n\n\n\n### [Notable Approvals | Drugs](/drugs/news-events-human-drugs/notable-approvals-drugs)\n\n\n\nNews about human drug-related approvals\n\n\n\n\n\n\n\n### [Complex Generics News](/drugs/generic-drugs/complex-generics-news)\n\n\n\nUp-to-date information on FDA’s actions on complex generics\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCenter\n\n\n\n\n\n\n\n\n\n## Recently published Drug-related Guidances\n\n\n\n\n\n\n\n\n\n\n\n\n\n Sep 08\n\n\n\n### [Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates](/regulatory-information/search-fda-guidance-documents/temporary-policies-compounding-certain-starter-parenteral-nutrition-drug-products-neonates)\n\n\n\n\n\n\n\n\n\n\n\n Sep 02\n\n\n\n### [Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling](/regulatory-information/search-fda-guidance-documents/pharmacokinetics-patients-impaired-hepatic-function-study-design-data-analysis-and-impact-dosing-and)\n\n\n\n\n\n\n\n\n\n\n\n Aug 21\n\n\n\n### [Evaluation of Therapeutic Equivalence](/regulatory-information/search-fda-guidance-documents/evaluation-therapeutic-equivalence)\n\n\n\n\n\n\n\n\n\n [FDA Guidance Search](/regulatory-information/search-fda-guidance-documents)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Drugs Databases\n\n\n\n\n\n\n\n\n\n### [Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm)\n\n\n\nFind information about most FDA-approved prescription, generic, and over-the-counter drug products\n\n\n\n\n\n\n\n### [FDA Drug Shortages Database](https://dps.fda.gov/drugshortages)\n\n\n\nFind information about drug shortages caused by manufacturing and quality problems, delays, and discontinuations\n\n\n\n\n\n\n\n### [Orange Book](https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm)\n\n\n\nThe Orange Book identifies drug products approved by FDA on the basis of safety and effectiveness\n\n\n\n\n\n\n\n### [National Drug Code Directory Search](https://dps.fda.gov/ndc)\n\n\n\nFind information about finished drug products, unfinished drugs, and compounded drug products.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n##\n\n\n\nParagraph Header\n\n\n\nContact FDA\n\n\n\n\n\n\n\n\n\nContact Point\n\n\n\n\n\nDivision of Drug Information\n U.S. Food and Drug Administration\n 10903 New Hampshire Avenue\n Building 51, Room 1109\n Silver Spring, MD 20993\n\n\n\n\n\n\n[druginfo@fda.hhs.gov](mailto:druginfo@fda.hhs.gov)\n\n\n\n\n\n\n\nToll Free\n\n\n\n(855) 543-3784\n\n\n\n(301) 796-3400\n\n\n\n\n\n\n\n\n\n\n\n\n\nHours Available\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCenter for Drug Evaluation and Research (CDER)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n## For Latest Updates Follow\n\n\n\n\n\nContact Point Twitter\n\n\n\n\n\n## [@FDAdrugs](https://x.com/FDAdrugs)\n\n\n\nYour source for the latest drug information.\n Know the moment it happens.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n07/24/2024\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\nSubscribe to What's New Related to Drugs\n\n Get regular FDA email updates delivered on this topic to your inbox.\n\n\n\n Enter your email address to subscribe:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 12604,
"content_type": "text/html",
"description": "News & Events for Human Drugs",
"status_code": 200,
"success": true,
"title": "News & Events for Human Drugs | FDA",
"url": "https://www.fda.gov/drugs/news-events-human-drugs"
},
"error": "",
"elapsed": 0.510404433
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Novel drug approvals list 2026",
"max_age_seconds": 3600,
"url": "https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda"
},
"dispatch_id": "toolu_011R23xEJFhvchLTzGTiBgSo",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_011R23xEJFhvchLTzGTiBgSo",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Novel drug approvals list 2026",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda"
}
},
"status": "running",
"updatedAt": 1789169280263
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_011R23xEJFhvchLTzGTiBgSo",
"status": "completed",
"result": {
"content": "Novel Drug Approvals at FDA | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - [Development & Approval Process | Drugs](/drugs/development-approval-process-drugs)\n - Novel Drug Approvals at FDA\n\n\n - [Development & Approval Process | Drugs](/drugs/development-approval-process-drugs)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [Novel Drug Approvals at FDA](/drugs/development-approval-process-drugs/novel-drug-approvals-fda)\n\n\n\n\n - [Novel Drug Approvals for 2026](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)\n - [Novel Drug Approvals for 2025](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)\n - [Novel Drug Approvals for 2024](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)\n - [Novel Drug Approvals for 2023](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)\n - [Novel Drug Approvals for 2022](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)\n - [Novel Drug Approvals for 2021](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# Novel Drug Approvals at FDA\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Novel Drug Approvals at FDA](/drugs/development-approval-process-drugs/novel-drug-approvals-fda)\n\n\n\n\n - [Novel Drug Approvals for 2026](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)\n - [Novel Drug Approvals for 2025](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)\n - [Novel Drug Approvals for 2024](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)\n - [Novel Drug Approvals for 2023](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)\n - [Novel Drug Approvals for 2022](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)\n - [Novel Drug Approvals for 2021](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n## What are \"Novel\" Drugs?\n\n\"Novel\" drugs are new drugs never before approved or marketed in the U.S. See [Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/) for information about all of CDER’s approved drugs and biological products. \n\n## Helping Guide the Way for New Medicines\n\nInnovative drugs often mean new treatment options for patients and advances in health care for the American public. When it comes the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) provides clarity to drug developers on the necessary study design elements and other data needed in the drug application to support a full and comprehensive assessment. To do so, CDER relies on its understanding of the science used to create new products, testing and manufacturing procedures, and the diseases and conditions that new products are designed to treat. \n\n## A Wide Range of Products\n\nEach year, CDER approves a wide range of new drugs and biological products: \n\n- Some of these products have never been used in clinical practice. Below is a listing of new molecular entities and new therapeutic biological products approved by CDER and organized by calendar year. This listing does not contain vaccines, allergenic products, blood and blood products, plasma derivatives, cellular and gene therapy products, or other products approved by the [Center for Biologics Evaluation and Research](/vaccines-blood-biologics/development-approval-process-cber/biological-approvals-year).\n- Others are the same as, or related to, previously approved products, and they will compete with those products in the marketplace. See [Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/) for information about all of CDER’s approved drugs and biological products. \n\n## New Molecular Entities (NMEs)\n\nCertain drugs are classified as new molecular entities (“NMEs”) for purposes of FDA review. Many of these products contain active moieties that FDA had not previously approved, either as a single ingredient drug or as part of a combination product. These products frequently provide important new therapies for patients. Some drugs are characterized as NMEs for administrative purposes, but nonetheless contain active moieties that are closely related to active moieties in products that FDA has previously approved. FDA’s classification of a drug as an “NME” for review purposes is distinct from FDA’s determination of whether a drug product is a “new chemical entity” or “NCE” within the meaning of the Federal Food, Drug, and Cosmetic Act. \n\n**2015-2020 Reports are available in the **[FDA Archive](https://web.archive.org/web/20240418171144/https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda)\n\n## New Molecular Entity and New Therapeutic Biological Product Approvals (CDER only)\n\n- [Novel Drug Approvals for 2026](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)\n- [Novel Drug Approvals for 2025](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)\n- [Novel Drug Approvals for 2024](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)\n- [Novel Drug Approvals for 2023](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)\n- [Novel Drug Approvals for 2022](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)\n- [Novel Drug Approvals for 2021](/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021)\n\n## Drug Approval Information (CDER only)\n\n- [Recent New and Generic Drug Approvals](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=%5BREDACTED%5D)\n- [Drug Approval Reports by Month](http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=%5BREDACTED%5D)\n- [Drug and Biologic Approval and IND Activity Reports](/drugs/how-drugs-are-developed-and-approved/drug-and-biologic-approval-and-ind-activity-reports)\n\n## Related Information from Other FDA Centers\n\n- [Innovation and Regulatory Science (CBER)](/vaccines-blood-biologics/science-research-biologics/innovation-and-regulatory-science)\n\n## Resources\n\n- [Compilation of CDER New Molecular Entity (NME) Drug and New Biologic Approvals](/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals)\n- [Prescribing Information Resources](/node/356177)\n- [Frequently Asked Questions: Breakthrough Therapies](/regulatory-information/food-and-drug-administration-safety-and-innovation-act-fdasia/frequently-asked-questions-breakthrough-therapies)\n- [Critical Path Innovation Meetings (CPIM)](/drugs/drug-innovation/critical-path-innovation-meetings-cpim)\n - [CPIM FAQ's](/drugs/drug-innovation/critical-path-innovation-meeting-cpim-faqs)\n - [CPIM Topics Held to Date](/drugs/drug-innovation/critical-path-innovation-meeting-cpim-topics-held-date)\n\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n07/21/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 10795,
"content_type": "text/html",
"description": "Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process.",
"status_code": 200,
"success": true,
"title": "Novel Drug Approvals at FDA | FDA",
"url": "https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda"
},
"error": "",
"elapsed": 0.101785937
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Notable drug approvals recent",
"max_age_seconds": 3600,
"url": "https://www.fda.gov/drugs/news-events-human-drugs/notable-approvals-drugs"
},
"dispatch_id": "toolu_0149a1QuAdYU93M4QcRJrPeZ",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_0149a1QuAdYU93M4QcRJrPeZ",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Notable drug approvals recent",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/news-events-human-drugs/notable-approvals-drugs"
}
},
"status": "running",
"updatedAt": 1789169280266
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_0149a1QuAdYU93M4QcRJrPeZ",
"status": "completed",
"result": {
"content": "Notable Approvals | Drugs | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n - Notable Approvals | Drugs\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops | Drugs](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# Notable Approvals | Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n| Title | Date Posted | Brand Name | Active Ingredient |\n| [FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy](/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy) | 9/11/2026 | Isembyld | apitegromab-mstn |\n| [FDA approves first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system](/drugs/news-events-human-drugs/fda-approves-first-treatment-children-aged-4-11-years-apds-rare-genetic-disorder-immune-system) | 9/11/2026 | Joenja | leniolisib |\n| [FDA Approves Treatment for Essential Thrombocythemia](/drugs/news-events-human-drugs/fda-approves-treatment-essential-thrombocythemia) | 8/31/2026 | Besremi | ropeginterferon alfa-2b-njft |\n| [FDA Approves Stelara for Pediatric Ulcerative Colitis](/drugs/news-events-human-drugs/fda-approves-stelara-pediatric-ulcerative-colitis) | 8/28/2026 | Stelara | ustekinumab |\n| [FDA Approves Drug to Treat HIV Infection in Newborns](/drugs/news-events-human-drugs/fda-approves-drug-treat-hiv-infection-newborns) | 8/25/2026 | Tivicay PD | dolutegravir |\n| [FDA Approves First Drug for Warm Autoimmune Hemolytic Anemia](/drugs/news-events-human-drugs/fda-approves-first-drug-warm-autoimmune-hemolytic-anemia) | 8/25/2026 | Imaavy | nipocalimab-aahu |\n| [FDA Approves Second Treatment for Fibrodysplasia Ossificans Progressiva](/drugs/news-events-human-drugs/fda-approves-second-treatment-fibrodysplasia-ossificans-progressiva) | 8/19/2026 | Pasatru | garetosmab-grts |\n| [FDA Approves First Nonprescription Fixed-Dose Combination of Acetaminophen and Naproxen Sodium for 12-Hour Pain Relief](/drugs/news-events-human-drugs/fda-approves-first-nonprescription-fixed-dose-combination-acetaminophen-and-naproxen-sodium-12-hour) | 7/24/2026 | Tylenol with Naproxen | acetaminophen and naproxen sodium |\n| [FDA Approves First Oral Therapy that Inhibits Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) to Lower Bad Cholesterol in Adults with High Cholesterol](/drugs/news-events-human-drugs/fda-approves-first-oral-therapy-inhibits-proprotein-convertase-subtilisinkexin-type-9-pcsk9-lower) | 7/16/2026 | Lipfendra | enlicitide |\n| [FDA Approves First At-home Starting Dose for Alzheimer’s Disease Treatment](/drugs/news-events-human-drugs/fda-approves-first-home-starting-dose-alzheimers-disease-treatment) | 7/13/2026 | Leqembi | lecanemab-irmb |\n| [FDA Approves New Treatment to Reduce Proteinuria in Adults with Primary Immunoglobulin A Nephropathy](/drugs/news-events-human-drugs/fda-approves-new-treatment-reduce-proteinuria-adults-primary-immunoglobulin-nephropathy) | 7/7/2026 | Trutakna | atacicept-vymj |\n| [FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia](/drugs/news-events-human-drugs/fda-approves-first-treatment-shown-reduce-risk-acute-pancreatitis-adults-severe-hypertriglyceridemia) | 6/24/2026 | Tryngolza | olezarsen |\n| [FDA approves first oral carbapenem therapy for complicated urinary tract infections](/drugs/news-events-human-drugs/fda-approves-first-oral-carbapenem-therapy-complicated-urinary-tract-infections) | 6/17/2026 | Utebzi | tebipenem pivoxil |\n| [FDA Approves Drug for Pediatric Stage 3 Type I Diabetes](/drugs/news-events-human-drugs/fda-approves-drug-pediatric-stage-3-type-i-diabetes) | 6/12/2026 | Tzield | teplizumab |\n| [FDA approves first interchangeable biosimilars to Simponi and Simponi Aria (golimumab) to treat rheumatoid arthritis and ulcerative colitis](/drugs/news-events-human-drugs/fda-approves-first-interchangeable-biosimilars-simponi-and-simponi-aria-golimumab-treat-rheumatoid) | 5/15/2026 | Immgolis | golimumab-sldi |\n| [FDA approves drug for pediatric patients with most common form of dwarfism](/drugs/news-events-human-drugs/fda-approves-drug-pediatric-patients-most-common-form-dwarfism) | 3/4/2026 | Yuviwel | navepegritide |\n| [FDA approves drug for adult and pediatric patients aged 6 and older with allergic fungal rhinosinusitis](/drugs/news-events-human-drugs/fda-approves-drug-adult-and-pediatric-patients-aged-6-and-older-allergic-fungal-rhinosinusitis) | 2/24/2026 | Dupixent | dupilumab |\n| [FDA approves therapy for rare blood disorder in pediatric patients 12 years and older](/drugs/news-events-human-drugs/fda-approves-therapy-rare-blood-disorder-pediatric-patients-12-years-and-older) | 1/5/2026 | Cablivi | caplacizumab-yhdp |\n| [FDA approves first oral treatment for anemia in thalassemia, an inherited blood disorder](/drugs/news-events-human-drugs/fda-approves-first-oral-treatment-anemia-thalassemia-inherited-blood-disorder) | 1/5/2026 | Aqvesme | mitapivat |\n| [FDA approves first drug to treat serious complication of stem cell transplant](/drugs/news-events-human-drugs/fda-approves-first-drug-treat-serious-complication-stem-cell-transplant) | 1/5/2026 | Yartemlea | narsoplimab-wuug |\n| [FDA approves first prescription oral medicine for iron deficiency in pediatric patients ages 10 and older](/drugs/news-events-human-drugs/fda-approves-first-prescription-oral-medicine-iron-deficiency-pediatric-patients-ages-10-and-older) | 12/22/2025 | Accrufer | ferric maltol |\n| [FDA approves drug to improve functional capacity and symptoms in adults with rare inherited heart condition](/drugs/news-events-human-drugs/fda-approves-drug-improve-functional-capacity-and-symptoms-adults-rare-inherited-heart-condition) | 12/22/2025 | Myqorzo | aficamten |\n| [FDA approves drug to treat chronic, progressive lung disease](/drugs/news-events-human-drugs/fda-approves-drug-treat-chronic-progressive-lung-disease) | 12/19/2025 | Jascayd | nerandomilast |\n| [FDA approves drug for type of abnormally fast heart rhythm](/drugs/news-events-human-drugs/fda-approves-drug-type-abnormally-fast-heart-rhythm) | 12/15/2025 | Cardamyst | etripamil |\n| [FDA approves a new treatment for primary immunoglobulin A nephropathy](/drugs/news-events-human-drugs/fda-approves-new-treatment-primary-immunoglobulin-nephropathy) | 11/25/2025 | Voyxact | sibeprenlimab-szsi |\n| [FDA approves drug to reduce triglycerides in adults with familial chylomicronemia syndrome](/drugs/news-events-human-drugs/fda-approves-drug-reduce-triglycerides-adults-familial-chylomicronemia-syndrome) | 11/18/2025 | Redemplo | plozasiran |\n| [FDA approves first interchangeable biosimilar to Perjeta to treat certain types of breast cancer](/drugs/news-events-human-drugs/fda-approves-first-interchangeable-biosimilar-perjeta-treat-certain-types-breast-cancer) | 11/13/2025 | Poherdy | pertuzumab-dpzb |\n| [FDA approves 1st drug for children 7 years and older with irritable bowel syndrome with constipation](/drugs/news-events-human-drugs/fda-approves-1st-drug-children-7-years-and-older-irritable-bowel-syndrome-constipation) | 11/5/2025 | Linzess | linaclotide |\n| [FDA approves 1st drug for thymidine kinase 2 deficiency, a very rare mitochondrial disease](/drugs/news-events-human-drugs/fda-approves-1st-drug-thymidine-kinase-2-deficiency-very-rare-mitochondrial-disease) | 11/3/2025 | Kygevvi | doxecitine and doxribtimine |\n| [FDA approves drug to treat idiopathic pulmonary fibrosis](/drugs/news-events-human-drugs/fda-approves-drug-treat-idiopathic-pulmonary-fibrosis) | 10/7/2025 | Jascayd | nerandomilast |\n| [FDA approves new treatment for acromegaly, a rare endocrine disorder](/drugs/news-events-human-drugs/fda-approves-new-treatment-acromegaly-rare-endocrine-disorder) | 9/26/2025 | Palsonify | paltusotine |\n| [FDA approves drug to treat adults with persistent or chronic immune thrombocytopenia](/drugs/news-events-human-drugs/fda-approves-drug-treat-adults-persistent-or-chronic-immune-thrombocytopenia) | 9/2/2025 | Wayrilz | rilzabrutinib |\n| [FDA approves treatment for serious liver disease known as ‘MASH’](/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash) | 8/15/2025 | Wegovy | semaglutide |\n| [FDA approves first treatment for adults with complement 3 glomerulopathy, a rare kidney disease, to reduce proteinuria](/drugs/news-events-human-drugs/fda-approves-first-treatment-adults-complement-3-glomerulopathy-rare-kidney-disease-reduce) | 3/20/2025 | Fabhalta | iptacopan |\n| [FDA approves drug to prevent or reduce the frequency of bleeding episodes for patients with hemophilia A with inhibitors or hemophilia B with inhibitors](/drugs/news-events-human-drugs/fda-approves-drug-prevent-or-reduce-frequency-bleeding-episodes-patients-hemophilia-inhibitors-or) | 12/20/2024 | Alhemo | concizumab-mtci |\n| [FDA approves drug to reduce triglycerides in adult patients with familial chylomicronemia syndrome](/drugs/news-events-human-drugs/fda-approves-drug-reduce-triglycerides-adult-patients-familial-chylomicronemia-syndrome) | 12/19/2024 | Tryngolza | olezarsen |\n| [FDA approves drug for heart disorder caused by transthyretin-mediated amyloidosis](/drugs/news-events-human-drugs/fda-approves-drug-heart-disorder-caused-transthyretin-mediated-amyloidosis) | 11/25/2024 | Attruby | acoramidis |\n| [FDA approves new treatment for women with uncomplicated UTIs](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-treatment-uncomplicated-urinary-tract-infections-adult-women-who-have-limited-or-no) | 10/23/2024 | Orlynvah | sulopenem etzadroxil and probenecid |\n| [FDA approves imaging drug for evaluation of myocardial ischemia and infarction](/drugs/news-events-human-drugs/fda-approves-imaging-drug-evaluation-myocardial-ischemia-and-infarction) | 9/27/2024 | Flyrcado | flurpiridaz F 18 |\n| [FDA approves new drug for hypoparathyroidism, a rare disorder](/drugs/news-events-human-drugs/fda-approves-new-drug-hypoparathyroidism-rare-disorder) | 8/12/2024 | Yorvipath | palopegteriparatide |\n| [FDA approves treatment for adults with Alzheimer’s disease](/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease) | 7/02/2024 | Kisunla | donanemab-azbt |\n| [FDA approves treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults](/drugs/news-events-human-drugs/fda-approves-treatment-chronic-inflammatory-demyelinating-polyneuropathy-cidp-adults) | 6/24/2024 | Vyvgart Hytrulo | efgartigimod alfa and hyaluronidase-qvfc |\n| [FDA approves first interchangeable biosimilars to Eylea to treat macular degeneration and other eye conditions](/drugs/news-events-human-drugs/fda-approves-first-interchangeable-biosimilars-eylea-treat-macular-degeneration-and-other-eye) | 5/20/2024 | Yesafili and Opuviz | aflibercept-jbvf and aflibercept-yszy |\n| [FDA approves first drug for WHIM syndrome, a rare disorder](/drugs/news-events-human-drugs/fda-approves-first-drug-whim-syndrome-rare-disorder-can-lead-recurrent-life-threatening-infections) | 4/29/2024 | Xolremdi | mavorixafor |\n| [FDA approves imaging drug to assist in detection of cancerous tissue following lumpectomy](/drugs/news-events-human-drugs/fda-approves-imaging-drug-assist-detection-cancerous-tissue-following-lumpectomy) | 4/17/2024 | Lumisight | pegulicianine |\n| [FDA approves first interchangeable biosimilars to Prolia and Xgeva to treat certain types of osteoporosis and prevent bone events in cancer](/drugs/news-events-human-drugs/fda-approves-first-interchangeable-biosimilars-prolia-and-xgeva-treat-certain-types-osteoporosis-and) | 3/5/2024 | Jubbonti and Wyost | Denosumab-bbdz |\n| [FDA approves new drug under special pathway for patients receiving hemodialysis](/drugs/news-events-human-drugs/fda-approves-new-drug-under-special-pathway-patients-receiving-hemodialysis) | 11/15/2023 | Defencath | taurolidine and heparin |\n| [FDA approves first biosimilar to Actemra to treat adult and pediatric arthritis](/drugs/news-events-human-drugs/fda-approves-first-biosimilar-actemra-treat-adult-and-pediatric-arthritis) | 9/29/2023 | Tofidence | tocilizumab-bavi |\n| [FDA approves multiple generics of ADHD and BED treatment](/drugs/news-events-human-drugs/fda-approves-multiple-generics-adhd-and-bed-treatment) | 8/28/2023 | Vyvanse | lisdexamfetamine dimesylate |\n| [FDA approves first treatment for CD55-deficient protein-losing enteropathy (CHAPLE disease)](/drugs/news-events-human-drugs/fda-approves-first-treatment-cd55-deficient-protein-losing-enteropathy-chaple-disease) | 8/18/2023 | Veopoz | pozelimab-bbfg |\n| [FDA approves first treatment for Fibrodysplasia Ossificans Progressiva](/drugs/news-events-human-drugs/fda-approves-first-treatment-fibrodysplasia-ossificans-progressiva) | 8/17/2023 | Sohonos | palovarotene |\n| [FDA approves first treatment for molluscum contagiosum](/drugs/news-events-human-drugs/fda-approves-first-treatment-molluscum-contagiosum) | 7/24/2023 | Ycanth | cantharidin |\n| [FDA approves first treatment for pediatric functional constipation](/drugs/news-events-human-drugs/fda-approves-first-treatment-pediatric-functional-constipation) | 6/12/2023 | Linzess | linaclotide |\n| [FDA approves treatment for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma](/drugs/news-events-human-drugs/fda-approves-treatment-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell) | 5/19/2023 | Epkinkly | epcoritamab-bysp |\n| [FDA approves first oral treatment for moderately to severely active Crohn’s disease](/drugs/news-events-human-drugs/fda-approves-first-oral-treatment-moderately-severely-active-crohns-disease) | 5/18/2023 | Rinvoq | upadacitinib |\n| [FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene](/drugs/news-events-human-drugs/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene) | 4/25/2023 | Qalsody | tofersen |\n| [FDA approves first treatment for activated phosphoinositide 3-kinase delta syndrome](/drugs/news-events-human-drugs/fda-approves-first-treatment-activated-phosphoinositide-3-kinase-delta-syndrome) | 3/24/2023 | Joenja | leniolisib |\n| [FDA approves first treatment for Rett Syndrome](/drugs/news-events-human-drugs/fda-approves-first-treatment-rett-syndrome) | 3/13/2023 | Daybue | trofinetide |\n| [FDA approves first treatment for Friedreich’s ataxia](/drugs/news-events-human-drugs/fda-approves-first-treatment-friedreichs-ataxia) | 2/28/2023 | Skyclarys | omaveloxolone |\n| [FDA approves first enzyme replacement therapy for rare alpha-mannosidosis](/drugs/news-events-human-drugs/fda-approves-first-enzyme-replacement-therapy-rare-alpha-mannosidosis) | 2/17/2023 | Lamzede | velmanase alfa-tycv |\n| [FDA approves drug combination treatment for adults with asthma](/drugs/news-events-human-drugs/fda-approves-drug-combination-treatment-adults-asthma) | 1/10/2023 | Airsupra | albuterol-budesonide |\n| [FDA approves imaging drug to help identify lung cancer lesions](/drugs/news-events-human-drugs/fda-approves-imaging-drug-help-identify-lung-lesions-during-surgery) | 12/16/2022 | Cytalux | pafolacianine |\n| [FDA approves first treatment for prurigo nodularis](/drugs/news-events-human-drugs/fda-approves-first-treatment-prurigo-nodularis) | 9/28/2022 | Dupixent | dupilumab |\n| [FDA approves treatment to improve kidney function in adults with hepatorenal syndrome](/drugs/news-events-human-drugs/fda-approves-treatment-improve-kidney-function-adults-hepatorenal-syndrome) | 9/14/2022 | Terlivaz | terlipressin |\n| [FDA approves topical treatment addressing repigmentation in vitiligo in patients aged 12 and older](/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older) | 7/19/2022 | Opzelura | ruxolitinib |\n| [FDA approves treatment for chronic weight management in pediatric patients aged 12 years and older](/drugs/news-events-human-drugs/fda-approves-treatment-chronic-weight-management-pediatric-patients-aged-12-years-and-older) | 6/24/2022 | Qsymia | phentermine and topiramate |\n| [FDA approves treatment for weight management in patients with Bardet-Biedl Syndrome aged 6 or older](/drugs/news-events-human-drugs/fda-approves-treatment-weight-management-patients-bardet-biedl-syndrome-aged-6-or-older) | 6/16/2022 | Imcivree | setmelanotide |\n| [FDA Approves Oral Form for the treatment of adults with amyotrophic lateral sclerosis (ALS)](/drugs/news-events-human-drugs/fda-approves-oral-form-treatment-adults-amyotrophic-lateral-sclerosis-als) | 5/12/2022 | Radicava ORS | edaravone |\n| [FDA approves new drug to improve heart function in adults with rare heart condition](/drugs/news-events-human-drugs/fda-approves-new-drug-improve-heart-function-adults-rare-heart-condition) | 4/29/2022 | Camzyos | mavacamten |\n| [FDA approves drug for treatment of seizures associated with rare disease in patients two years of age and older](/drugs/news-events-human-drugs/fda-approves-drug-treatment-seizures-associated-rare-disease-patients-two-years-age-and-older) | 3/18/2022 | Ztalmy | ganaxolone |\n| [FDA approves drug for adults with rare form of bone marrow disorder](/drugs/news-events-human-drugs/fda-approves-drug-adults-rare-form-bone-marrow-disorder) | 2/28/2022 | Vonjo | pacritinib |\n| [FDA approves treatment for anemia in adults with rare inherited disorder](/drugs/news-events-human-drugs/fda-approves-treatment-anemia-adults-rare-inherited-disorder) | 2/17/2022 | Pyrukynd | mitapivat |\n| [FDA approves treatment for adults with rare type of anemia](/drugs/news-events-human-drugs/fda-approves-treatment-adults-rare-type-anemia) | 2/4/2022 | Enjaymo | sutimlimab-jome |\n| [FDA approves add-on therapy to lower cholesterol among certain high-risk adults](/drugs/news-events-human-drugs/fda-approves-add-therapy-lower-cholesterol-among-certain-high-risk-adults) | 12/22/2021 | Leqvio | inclisiran |\n| [FDA approves drug to treat, help prevent types of blood clots in certain pediatric populations](/drugs/news-events-human-drugs/fda-approves-drug-treat-help-prevent-types-blood-clots-certain-pediatric-populations) | 12/20/2021 | Xarelto | rivaroxaban |\n| [FDA approves Tezspire as maintenance treatment for severe asthma](/drugs/news-events-human-drugs/fda-approves-maintenance-treatment-severe-asthma) | 12/17/2021 | Tezspire | tezepelumab-ekko |\n| [FDA approves drug to treat sickle cell disease in patients aged 4 up to 11 years](/drugs/news-events-human-drugs/fda-approves-drug-treat-sickle-cell-disease-patients-aged-4-11-years) | 12/17/2021 | Oxbryta | voxelotor |\n| [FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease](/drugs/fda-approves-first-drug-decrease-urine-protein-iga-nephropathy-rare-kidney-disease) | 12/15/2021 | Tarpeyo | budesonide |\n| [FDA approves naloxone injection to counteract opioid overdoses](/drugs/news-events-human-drugs/fda-approves-naloxone-injection-counteract-opioid-overdoses) | 10/15/2021 | ZIMHI | naloxone hydrochloride |\n| [FDA approves add-on drug for adults with rare form of blood vessel inflammation](/drugs/news-events-human-drugs/fda-approves-add-drug-adults-rare-form-blood-vessel-inflammation) | 10/13/2021 | Tavneos | avacopan |\n| [FDA approves add-on drug for ages 10 & up with rare forms of high cholesterol](/drugs/news-events-human-drugs/fda-approves-add-drug-ages-10-rare-forms-high-cholesterol) | 9/24/2021 | Repatha | evolocumab |\n| [FDA approves new use of transplant drug based on real-world evidence](/drugs/news-events-human-drugs/fda-approves-new-use-transplant-drug-based-real-world-evidence) | 7/16/2021 | Prograf | tacrolimus |\n| [FDA approves drug to reduce risk of serious kidney and heart complications in adults with chronic kidney disease associated with type 2 diabetes](/drugs/news-events-human-drugs/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease) | 7/9/2021 | Kerendia | finerenone |\n| [FDA approves therapy for pediatric patients with serious rare blood disease](/drugs/news-events-human-drugs/fda-approves-therapy-pediatric-patients-serious-rare-blood-disease) | 6/7/2021 | Ultomiris | ravulizumab-cwvz |\n| [FDA approves drug to treat smallpox](/drugs/news-events-human-drugs/fda-approves-drug-treat-smallpox) | 6/4/2021 | Tembexa | brincidofovir |\n| [FDA approves second PSMA-targeted PET imaging drug for men with prostate cancer](/drugs/news-events-human-drugs/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer) | 5/27/2021 | Pylarify | piflufolastat F 18 |\n| [FDA approves new treatment for adults with serious rare blood disease](/drugs/news-events-human-drugs/fda-approves-new-treatment-adults-serious-rare-blood-disease) | 5/14/2021 | Empaveli | pegcetacoplan |\n| [FDA approves add-on therapy for patients with genetic form of severely high cholesterol](/drugs/news-events-human-drugs/fda-approves-add-therapy-patients-genetic-form-severely-high-cholesterol) | 4/1/2021 | Praluent | alirocumab |\n| [FDA approves first treatment for disease that causes recurrent inflammation in sac surrounding heart](/drugs/news-events-human-drugs/fda-approves-first-treatment-disease-causes-recurrent-inflammation-sac-surrounding-heart) | 3/18/2021 | Arcalyst | rilonacept |\n| [FDA approves add-on therapy for patients with genetic form of severely high cholesterol](/drugs/news-events-human-drugs/fda-approves-add-therapy-patients-genetic-form-severely-high-cholesterol-0) | 2/11/2021 | Evkeeza | evinacumab-dgnb |\n| [FDA approves treatment for ebola virus](/drugs/news-events-human-drugs/fda-approves-treatment-ebola-virus) | 12/21/2020 | Ebanga | Ansuvimab-zykl |\n| [FDA approves weight management drug for patients aged 12 and older](/drugs/news-events-human-drugs/fda-approves-weight-management-drug-patients-aged-12-and-older) | 12/4/2020 | Saxenda | liraglutide |\n| [FDA approves first treatment for weight management for people with certain rare genetic conditions](/drugs/news-events-human-drugs/fda-approves-first-treatment-weight-management-people-certain-rare-genetic-conditions) | 11/27/2020 | Imcivree | setmelanotide |\n| [FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness](/drugs/news-events-human-drugs/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness) | 10/22/2020 | Veklury | remdesivir |\n| [FDA approves weekly therapy for adult growth hormone deficiency](/drugs/news-events-human-drugs/fda-approves-weekly-therapy-adult-growth-hormone-deficiency) | 9/1/2020 | Sogroya | somapacitan |\n| [FDA approves new treatment for rare hereditary disease](/drugs/news-events-human-drugs/fda-approves-new-treatment-rare-hereditary-disease) | 8/23/2018 | Takhzyro | lanadelumab |\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n09/11/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 28223,
"content_type": "text/html",
"description": "News about human drug-related approvals",
"status_code": 200,
"success": true,
"title": "Notable Approvals | Drugs | FDA",
"url": "https://www.fda.gov/drugs/news-events-human-drugs/notable-approvals-drugs"
},
"error": "",
"elapsed": 0.105028305
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Isembyld apitegromab details",
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy"
},
"dispatch_id": "toolu_014UxCPJARg2y8GiMrMzqY3h",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_014UxCPJARg2y8GiMrMzqY3h",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Isembyld apitegromab details",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy"
}
},
"status": "running",
"updatedAt": 1789169288578
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_014UxCPJARg2y8GiMrMzqY3h",
"status": "completed",
"result": {
"content": "FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n - FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops | Drugs](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Action\n\nThe U.S. Food and Drug Administration today approved Isembyld (apitegromab-mstn) injection to treat spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment. Isembyld is the first therapy approved for SMA that directly targets muscle loss, working alongside existing treatments to address a critical dimension of the disease.\n\n## Disease or Condition\n\nSMA is a rare, progressive neuromuscular disease affecting approximately 1 in 10,000 live births and is among the leading genetic causes of infant mortality. It is caused by a faulty SMN1 gene that fails to produce a protein essential for motor neuron survival, leading to progressive muscle weakness and wasting.\n\nA backup gene, SMN2, typically produces a broken version of this protein, and existing SMN2-targeted therapies work by correcting this defect so the body can produce enough of the missing protein to keep motor neurons alive. While these treatments have significantly improved outcomes for many patients, those with more advanced disease continue to experience substantial motor limitations (including the ability to walk or move independently), highlighting the need for therapies that directly address muscle loss.\n\n## Effectiveness\n\nThe effectiveness and safety of Isembyld were evaluated in a 52-week randomized, double-blind, placebo-controlled trial ([NCT05156320](https://clinicaltrials.gov/study/NCT05156320)). The trial enrolled 188 participants with SMA between age 2 to 21 years who were not able to move or walk independently. All participants were already receiving an approved SMN2-targeted treatment. Patients were randomly assigned to receive Isembyld 10 mg/kg, Isembyld 20 mg/kg via intravenous infusion, or placebo once every four weeks for approximately one year. The primary analysis was conducted in 156 patients aged 2 to 12 years.\n\nThe study measured change from baseline in the Hammersmith Functional Motor Scale Expanded, a standardized assessment of motor ability. Among patients aged 2 to 12 years, those receiving Isembyld 10 mg/kg showed a significant difference from those on placebo, with treated patients demonstrating improvement in motor function at one year while those on placebo declined. Those in the treatment arm were more than twice as likely than patients in the placebo arm to demonstrate a clinically meaningful improvement (34.2% vs. 13.5%).\n\n## Safety Information\n\nThe most common adverse reactions were upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, and pharyngitis (sore throat). An increased risk of fractures, including serious fractures, was observed in patients treated with Isembyld. Isembyld may cause fetal harm and may affect reproductive function.\n\n## Designation\n\nIsembyld was given [Fast Track](/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track), [Orphan Drug](/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products) and [Rare Pediatric Disease](/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs) designations. The approval of Isembyld was granted to Scholar Rock, Inc.\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n09/11/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 9160,
"content_type": "text/html",
"description": "The U.S. Food and Drug Administration today approved Isembyld (apitegromab-mstn) injection to treat spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment. Isembyld is the first therapy approved for SMA that dire",
"status_code": 200,
"success": true,
"title": "FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy | FDA",
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy"
},
"error": "",
"elapsed": 0.108362546
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Joenja leniolisib pediatric APDS details",
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-children-aged-4-11-years-apds-rare-genetic-disorder-immune-system"
},
"dispatch_id": "toolu_019inAzYKHjgCNHGS3FZQWJM",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_019inAzYKHjgCNHGS3FZQWJM",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Joenja leniolisib pediatric APDS details",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-children-aged-4-11-years-apds-rare-genetic-disorder-immune-system"
}
},
"status": "running",
"updatedAt": 1789169288582
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_019inAzYKHjgCNHGS3FZQWJM",
"status": "completed",
"result": {
"content": "FDA approves first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n - FDA approves first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops | Drugs](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# FDA approves first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Action\n\nFDA has approved Joenja (leniolisib) tablets as the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in children 4-11 years who weigh at least 27 kg. Joenja was first approved in 2023 for the same indication in patients 12 years and older at a dose of 70 mg orally twice a day. Children 4-11 years take a weight-based dosage (40, 50, or 70 mg) orally twice a day, approximately 12 hours apart.\n\n## Disease or Condition\n\nActivated PI3K delta syndrome (APDS) is a rare genetic disorder that impairs cells of the immune system. These cells are necessary to recognize and attack foreign invaders, such as viruses and bacteria, to prevent infection. People with APDS develop recurrent infections, particularly in the sinuses, ears, and respiratory tract. They also develop enlarged lymph nodes, tonsils, spleen, and other organs that can cause obstruction in the airway and gastrointestinal tract. Individuals with this condition often have low numbers of white blood cells, including red cells and platelets. Patients with APDS are more prone to develop blood cell cancers, like lymphoma.\n\nAPDS is caused by mutations in the PIK3CD or PIK3R1 genes that encode a protein called phosphoinositide-3 kinase delta (PI3K delta), which is important for the normal development and function of white blood cells in the body.\n\n## Effectiveness\n\nFor the original approval for patients 12 years and older with APDS, the efficacy of Joenja was evaluated in the placebo-controlled portion of Study 2201 ([NCT02435173](https://clinicaltrials.gov/study/NCT02435173)). This was a 12‑week blinded, randomized, placebo-controlled study of 31 patients 12 years and older with confirmed APDS-associated genetic PI3K delta mutations, with a documented variant in either PIK3CD or PIK3R1.\n\nDuring the study, 21 patients received 70 mg of Joenja and 10 received placebo twice a day for 12 weeks. The co‑primary efficacy endpoints were improvement in lymphoproliferation (lymph node reduction) and the normalization of immunophenotype as measured by the percentage of naïve B cells out of total B cells.\n\nBy day 85 of the study, patients taking Joenja saw a reduction in lymph node size and a 37 percent improvement in naïve B cells counts compared to placebo, indicating a correction of the underlying immune defect.\n\nFor the approval for patients aged 4-11 years, safety and pharmacokinetic data were established from a single-arm, open-label study ([Study LE 3301](https://clinicaltrials.gov/study/NCT05438407)). In this study, 8 patients received the recommended Joenja dosage based on body weight. The pharmacokinetic data demonstrated no clinically significant difference between patients younger or older than 12 years.\n\n## Safety Information\n\nThe most common side effects of Joenja in children aged 4-11 were stomach pain, respiratory tract infection, diarrhea, headache, cough, nausea, rhinitis, and alopecia. Patients with moderate-to-severe liver impairment should not use Joenja. See full prescribing information for additional information on risks associated with Joenja.\n\n## Designations\n\nJoenja received orphan drug designation, rare pediatric disease designation, and priority review.\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n09/11/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 9169,
"content_type": "text/html",
"description": "FDA has approved Joenja (leniolisib) tablets as the first treatment for activated phosphoinositide 3-kinase delta syndrome in children 4-11 years who weigh at least 27 kg. Joenja was first approved in 2023 for the same indication in patients 12 years and older at a dose of 70 mg orally twice a day.",
"status_code": 200,
"success": true,
"title": "FDA approves first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system | FDA",
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-children-aged-4-11-years-apds-rare-genetic-disorder-immune-system"
},
"error": "",
"elapsed": 0.123677302
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Besremi essential thrombocythemia details",
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-essential-thrombocythemia"
},
"dispatch_id": "toolu_01EKi7T5GckiJuZ8BqDbvfDz",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_01EKi7T5GckiJuZ8BqDbvfDz",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Besremi essential thrombocythemia details",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-essential-thrombocythemia"
}
},
"status": "running",
"updatedAt": 1789169288586
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_01EKi7T5GckiJuZ8BqDbvfDz",
"status": "completed",
"result": {
"content": "FDA Approves Treatment for Essential Thrombocythemia | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n - FDA Approves Treatment for Essential Thrombocythemia\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops | Drugs](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# FDA Approves Treatment for Essential Thrombocythemia\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Action\n\nThe U.S. Food and Drug Administration has approved Besremi (ropeginterferon alfa-2b-njft) injection for the treatment of adults with essential thrombocythemia.\n\nThe recommended starting dosage of Besremi is 250 mcg by subcutaneous (under the skin) injection. The dosage should be increased to 350 mcg at 2 weeks and then to the maintenance dosage of 500 mcg at 4 weeks. The maintenance dose should be given every 2 weeks unless a dose modification is required due to tolerability.\n\n## Disease or Condition\n\nEssential thrombocythemia is a rare blood disorder that causes the bone marrow to make too many platelets, which can increase the risk for blood clots and bleeding when the platelet count is very high. Platelets are small cell fragments in blood that help form clots to stop or prevent bleeding.\n\n## Effectiveness\n\nThe effectiveness of Besremi was evaluated in the [SURPASS ET study](https://clinicaltrials.gov/study/NCT04285086?cond=%5BREDACTED%5D&titles=%5BREDACTED%5D&viewType=%5BREDACTED%5D&rank=%5BREDACTED%5D), an open-label, multicenter, randomized study that compared Besremi to anagrelide for the treatment of essential thrombocythemia. The study enrolled 174 adults with essential thrombocythemia who had an inadequate response or intolerance to hydroxyurea; 91 patients received Besremi and 83 patients received anagrelide (another medicine approved for treating essential thrombocythemia).\n\nBesremi was administered subcutaneously every 2 weeks at the starting dose of 250 mcg (Week 0), then 350 mcg (Week 2), and 500 mcg (Week 4), and then remained fixed at 500 mcg every two weeks for the remainder of the study. Anagrelide was administered orally according to its product label and treatment practices. Patients in both arms also received low-dose aspirin (75 to 150 mg/day per local practice), unless contraindicated.\n\nEfficacy was evaluated in the SURPASS ET study by assessing durable Modified European Leukemia Net (ELN) response rates at Months 9 and 12. Patients were considered responders if they met all of the following criteria: blood count remission, improvement or non-progression of splenomegaly (enlarged spleen), and absence of bleeding or clotting events. Treatment with Besremi demonstrated a higher response rate of 37.4% compared to a response rate of 3.6% for the anagrelide treatment group at both Months 9 and 12.\n\n## Safety Information\n\nThe most common adverse reactions included transaminase elevations (high levels of liver enzymes), anemia, fever, bacterial infection, pruritus (itching), and weight loss. See the full prescribing information for all risks associated with Besremi.\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n08/31/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 8397,
"content_type": "text/html",
"description": "The U.S. Food and Drug Administration has approved Besremi (ropeginterferon alfa-2b-njft) injection for the treatment of adults with essential thrombocythemia.",
"status_code": 200,
"success": true,
"title": "FDA Approves Treatment for Essential Thrombocythemia | FDA",
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-essential-thrombocythemia"
},
"error": "",
"elapsed": 0.107774856
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "2026 novel drug approvals list with dates and sponsors",
"max_age_seconds": 3600,
"url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026"
},
"dispatch_id": "toolu_01JDXqvQMoSZ7iAcagoBJ3zb",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_01JDXqvQMoSZ7iAcagoBJ3zb",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "2026 novel drug approvals list with dates and sponsors",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026"
}
},
"status": "running",
"updatedAt": 1789169288590
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_01JDXqvQMoSZ7iAcagoBJ3zb",
"status": "completed",
"result": {
"content": "Novel Drug Approvals for 2026 | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - [Development & Approval Process | Drugs](/drugs/development-approval-process-drugs)\n - [Novel Drug Approvals at FDA](/drugs/development-approval-process-drugs/novel-drug-approvals-fda)\n - Novel Drug Approvals for 2026\n\n\n - [Novel Drug Approvals at FDA](/drugs/development-approval-process-drugs/novel-drug-approvals-fda)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [Novel Drug Approvals at FDA](/drugs/development-approval-process-drugs/novel-drug-approvals-fda)\n\n\n\n\n - [Novel Drug Approvals for 2026](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)\n - [Novel Drug Approvals for 2025](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)\n - [Novel Drug Approvals for 2024](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)\n - [Novel Drug Approvals for 2023](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)\n - [Novel Drug Approvals for 2022](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)\n - [Novel Drug Approvals for 2021](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# Novel Drug Approvals for 2026\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Novel Drug Approvals at FDA](/drugs/development-approval-process-drugs/novel-drug-approvals-fda)\n\n\n\n\n - [Novel Drug Approvals for 2026](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)\n - [Novel Drug Approvals for 2025](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)\n - [Novel Drug Approvals for 2024](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)\n - [Novel Drug Approvals for 2023](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)\n - [Novel Drug Approvals for 2022](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)\n - [Novel Drug Approvals for 2021](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n## What are \"Novel\" Drugs?\n\n\"Novel\" drugs are new drugs never before approved or marketed in the U.S. See [Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/) for information about all of CDER’s approved drugs and biological products.\n\n## FDA Novel Drug Therapy Approvals for 2026\n\n| No. | Drug Name | Active Ingredient | Approval Date | FDA-approved use on approval date* |\n| 39. | Isembyld | apitegromab-mstn | 9/11/2026 | To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment |\n| 38. | Etcamah | camizestrant | 9/4/2026 | To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy |\n| 37. | Zanvastro | zilganersen | 9/3/2026 | To treat Alexander disease in pediatric and adult patients |\n| 36. | Mimrylo | rusfertide | 8/28/2026 | To treat erythrocytosis in adults with polycythemia vera |\n| 35. | Lisraya | brepocitinib | 8/27/2026 | To treat dermatomyositis in adults |\n| 34. | Rasonque | daraxonrasib | 8/26/2026 | To treat metastatic pancreatic cancer |\n| 33. | Pasatru | garetosmab-grts | 8/19/2026 | To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva |\n| 32. | Zenbexus | iberdomide | 8/13/2026 | To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent |\n| 31. | Tauklarify | florquinitau F 18 | 8/13/2026 | To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology |\n| 30. | Orzeyful | oveporexton | 8/5/2026 | To treat narcolepsy type 1 |\n| 29. | Simtriyo | centanafadine | 7/24/2026 | To treat attention-deficit hyperactivity disorder |\n| 28. | Lytenava | bevacizumab-vikg | 7/24/2026 | To treat patients with neovascular (wet) age-related macular degeneration |\n| 27. | Jideytro | zidesamtinib | 7/22/2026 | To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor |\n| 26. | Lipfendra | enlicitide decanoate | 7/15/2026 | To reduce low-density lipoprotein cholesterol |\n| 25. | Revtorpyk | gedatolisib | 7/14/2026 | In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting |\n| 24. | Trutakna | atacicept-vymj | 7/7/2026 | To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression |\n| 23. | Lumvoa | veligrotug-vvze | 6/26/2026 | To treat thyroid eye disease |\n| 22. | Utebzi | tebipenem pivoxil | 6/17/2026 | To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options |\n| 21. | Ambelvist | gadoquatrane | 6/12/2026 | To detect and visualize lesions with abnormal vascularity, in conjunction with MRI |\n| 20. | Cypsedo | cipepofol | 5/29/2026 | To induce general anesthesia in adults undergoing surgery |\n| 19. | Xocova | ensitrelvir | 5/29/2026 | To use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19 |\n| 18. | Zaynich | cefepime and zidebactam | 5/29/2026 | To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms |\n| 17. | Decnupaz | pivekimab sunirine-pvzy | 5/27/2026 | To treat adults with blastic plasmacytoid dendritic cell neoplasm\n[Drug Trials Snapshot](/drugs/drug-trials-snapshots/drug-trials-snapshots-decnupaz) |\n| 16. | Hepcludex | bulevirtide-gmod | 5/22/2026 | To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis |\n| 15. | Baxfendy | baxdrostat | 5/15/2026 | To treat hypertension in combination with other antihypertensive drugs |\n| 14. | Beqalzi | sonrotoclax | 5/13/2026 | To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor |\n| 13. | Veppanu | vepdegestrant | 5/1/2026 | To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy |\n| 12. | Idvynso | doravirine and islatravir | 4/20/2026 | To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine |\n| 11. | Foundayo | orforglipron | 4/1/2026 | To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity |\n| 10. | Awiqli | insulin icodec-abae | 3/26/2026 | To improve glycemic control in adults with type 2 diabetes mellitus |\n| 9. | Lifyorli | relacorilant | 3/25/2026 | To treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic treatment regimens, at least one of which included bevacizumab |\n| 8. | Avlayah | tividenofusp alfa-eknm | 3/24/2026 | To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II) |\n| 7. | Icotyde | icotrokinra | 3/17/2026 | To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy \n[Drug Trials Snapshot](/drugs/drug-trials-snapshots/drug-trials-snapshots-icotyde) |\n| 6. | Lynavoy | linerixibat | 3/17/2026 | To treat cholestatic pruritus associated with primary biliary cholangitis |\n| 5. | Yuviwel | navepegritide | 2/27/2026 | To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses |\n| 4. | Loargys | pegzilarginase-nbln | 2/23/2026 | To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction |\n| 3. | Bysanti | milsaperidone | 2/20/2026 | To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder |\n| 2. | Adquey | difamilast | 2/12/2026 | To treat mild to moderate atopic dermatitis |\n| 1. | Zycubo | copper histidinate | 1/12/2026 | To treat Menkes disease\n[Drug Trials Snapshot](/drugs/drug-trials-snapshots/drug-trials-snapshots-zycubo) |\n\n---\n\n*The listed “FDA-approved use” on this page is for presentation purposes only. To see the FDA-approved conditions of use [e.g., indication(s), population(s), dosing regimen(s)] for each of these products, please see the most recently approved Prescribing Information (or Label) available at [Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm). You can search by drug name, active ingredient, or application number.\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n09/11/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 13692,
"content_type": "text/html",
"description": "FDA Novel Drug Therapy Approvals for 2026",
"status_code": 200,
"success": true,
"title": "Novel Drug Approvals for 2026 | FDA",
"url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026"
},
"error": "",
"elapsed": 0.132159043
}{
"tool_name": "web_search",
"tool_input": {
"q": "Etcamah camizestrant FDA approval sponsor AstraZeneca September 2026 label"
},
"dispatch_id": "toolu_013qM7v1V5mNZUgwEFhPRLEA",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_search"
}{
"tool_name": "web_search",
"dispatch_id": "toolu_013qM7v1V5mNZUgwEFhPRLEA",
"status": "completed",
"result": {
"count": 9,
"query": "Etcamah camizestrant FDA approval sponsor AstraZeneca September 2026 label",
"results": [
{
"link": "https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment",
"snippet": "FDA granted accelerated approval to Etcamah (camizestrant) in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) ... · 8 days ago",
"title": "FDA Grants Accelerated Approval to a New Breast Cancer ..."
},
{
"link": "https://www.astrazeneca.com/media-centre/press-releases/2026/etcamah-approved-us-for-hr-breast-cancer.html",
"snippet": "September 2026 Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by ... · 8 days ago",
"title": "Etcamah in combination with a CDK4/6 inhibitor approved ..."
},
{
"link": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative",
"snippet": "On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen ... · 8 days ago",
"title": "FDA grants accelerated approval to camizestrant"
},
{
"link": "https://www.astrazeneca.com/content/az-us/media/press-releases/2026/ETCAMAH-camizestrant-in-combination-with-a-CDK-4-6-inhibitor-approved-in-the-US-for-1st-line-advanced-HR-positive-breast-cancer.html",
"snippet": "September 2026 Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by ... · 8 days ago",
"title": "ETCAMAH® (camizestrant) in combination with a CDK4/6 ..."
},
{
"link": "https://kolpulse.com/uptempo-blog/etcamah-camizestrant-fda-approval-kols-agree-odac-vote?hs_amp=%5BREDACTED%5D",
"snippet": "On September 4, 2026 the FDA granted accelerated approval to Etcamah (camizestrant, AstraZeneca) plus a CDK4/6 inhibitor for HR+/HER2− advanced ... · 6 days ago",
"title": "Etcamah (Camizestrant) Approval: KOLs Who Agree With ..."
},
{
"link": "https://www.oncnursingnews.com/view/fda-approves-camizestrant-for-esr1-mutated-advanced-breast-cancer",
"snippet": "FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for adult patients with ESR1-mutated HR+/HER2- advanced breast cancer. · 8 days ago",
"title": "FDA Approves Camizestrant for ESR1-Mutated Advanced ..."
},
{
"link": "https://www.drugs.com/newdrugs/fda-grants-accelerated-approval-etcamah-camizestrant-combination-cdk4-6-inhibitor-advanced-hr-6877.html",
"snippet": "AstraZeneca's Etcamah (camizestrant) has been approved in the US for the treatment of adult patients with hormone receptor … reduced the risk of disease ...",
"title": "FDA Grants Accelerated Approval to Etcamah"
},
{
"link": "https://www.breastcancer.org/treatment/hormonal-therapy/camizestrant",
"snippet": "The medicine is a new treatment option for breast cancers with an ESR1 mutation. Written by. Jamie DePolo |Updated on September 10, 2026. · 1 day ago",
"title": "FDA Approves Camizestrant (Etcamah) for Advanced HR+/ ..."
},
{
"link": "https://www.onclive.com/view/fda-approves-camizestrant-plus-a-cdk4-6-inhibitor-for-emergent-esr1-mutated-hr-her2-advanced-breast-cancer",
"snippet": "The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ... · 8 days ago",
"title": "FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for ..."
}
],
"success": true
},
"error": "",
"elapsed": 1.082720325
}{
"tool_name": "web_search",
"tool_input": {
"q": "Zanvastro zilganersen FDA approval Alexander disease Ionis September 2026"
},
"dispatch_id": "toolu_012LrFbaZB4ePyETKxr8dbXv",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_search"
}{
"tool_name": "web_search",
"dispatch_id": "toolu_012LrFbaZB4ePyETKxr8dbXv",
"status": "completed",
"result": {
"count": 9,
"query": "Zanvastro zilganersen FDA approval Alexander disease Ionis September 2026",
"results": [
{
"link": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease",
"snippet": "Zanvastro is the first FDA-approved treatment for Alexander disease and the first therapy to directly target the protein buildup that drives the ... · Sep 3, 2026",
"title": "FDA Approves First Drug to Treat Alexander Disease"
},
{
"link": "https://ir.ionis.com/news-releases/news-release-details/zanvastrotm-zilganersen-approved-fda-first-and-only-disease",
"snippet": "ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and ... · Sep 3, 2026",
"title": "ZANVASTRO™ (zilganersen) approved by the FDA as ..."
},
{
"link": "https://www.endaxd.org/drug-development-ionis",
"snippet": "On September 3, 2026, the FDA approved ZANVASTROTM (zilganersen). Ionis announced FDA approval of ZANVASTRO (zilganersen), the first and only disease-modifying ...",
"title": "IONIS 373 (Zilganersen)"
},
{
"link": "https://www.ddw-online.com/fda-approves-first-disease-modifying-treatment-for-alexander-disease-43757-202609/",
"snippet": "The US Food and Drug Administration (FDA) has approved Ionis Pharmaceuticals' Zanvastro (zilganersen) for the treatment of Alexander disease ... · 4 days ago",
"title": "FDA approves first disease modifying treatment for ..."
},
{
"link": "https://ir.ionis.com/news-releases/news-release-details/ionis-announces-zilganersen-new-drug-application-alexander",
"snippet": "Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review March 23, 2026 date set for ... · Mar 23, 2026",
"title": "Ionis announces zilganersen New Drug Application for ..."
},
{
"link": "https://www.drugs.com/newdrugs/fda-approves-zanvastro-zilganersen-alexander-6876.html",
"snippet": "U.S. Food and Drug Administration (FDA) has approved Zanvastro (zilganersen) for the treatment of Alexander disease (AxD) in pediatric and ... · 1 day ago",
"title": "FDA Approves Zanvastro (zilganersen) for the Treatment of ..."
},
{
"link": "https://www.neurologylive.com/view/fda-approves-zilganersen-first-treatment-alexander-disease",
"snippet": "FDA approved Zanvastro (zilganersen), the first therapy to directly target the GFAP protein buildup that drives Alexander disease, ... · Sep 3, 2026",
"title": "FDA Approves Zilganersen, First Treatment for Alexander ..."
},
{
"link": "https://www.facebook.com/MedChemExpressLLC/posts/a-new-dawn-for-ultra-rare-alexanderdiseaseon-september-3-2026-the-fda-approved-z/1474206354731923/",
"snippet": "September 3, 2026, the #FDA approved Zanvastro (#zilganersen) from Ionis … the first FDA-approved treatment for Alexander disease",
"title": "FDA approves zanvastro for Alexander disease treatment ..."
},
{
"link": "https://www.reuters.com/legal/litigation/us-fda-approves-ionis-pharmas-therapy-treat-rare-brain-disorder-2026-09-03/",
"snippet": "Ionis Pharmaceuticals said on Friday it would price its newly approved therapy to treat Alexander disease at $285000 per dose, ... · 8 days ago",
"title": "Ionis Pharma prices first FDA-approved treatment for ..."
}
],
"success": true
},
"error": "",
"elapsed": 0.73958917
}{
"tool_name": "web_search",
"tool_input": {
"q": "Mimrylo rusfertide FDA approval polycythemia vera August 2026 sponsor"
},
"dispatch_id": "toolu_016AHJMLnMxgemLKAN7PyKYf",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_search"
}{
"tool_name": "web_search",
"dispatch_id": "toolu_016AHJMLnMxgemLKAN7PyKYf",
"status": "completed",
"result": {
"count": 9,
"query": "Mimrylo rusfertide FDA approval polycythemia vera August 2026 sponsor",
"results": [
{
"link": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder",
"snippet": "August 28, 2026. The U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera ... · Aug 28, 2026",
"title": "FDA Approves First Drug of Its Kind for Polycythemia Vera ..."
},
{
"link": "https://www.takeda.com/newsroom/newsreleases/2026/fda-approval-mimrylo/",
"snippet": "Takeda received U.S. FDA approval of MIMRYLO, a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV) · Aug 28, 2026",
"title": "FDA Approves MIMRYLO (rusfertide) for Polycythemia Vera"
},
{
"link": "https://www.oncnursingnews.com/view/fda-approves-rusfertide-first-in-class-hepcidin-mimetic-for-polycythemia-vera",
"snippet": "FDA approves rusfertide (Mimrylo), a first-in-class hepcidin mimetic that regulates iron to control erythrocytosis in patients with polycythemia ... · Sep 1, 2026",
"title": "FDA Approves Rusfertide, First-in-Class Hepcidin Mimetic ..."
},
{
"link": "https://www.curetoday.com/view/fda-approves-mimrylo-for-polycythemia-vera-offering-a-new-treatment-approach",
"snippet": "FDA approves Mimrylo (rusfertide) for adults with polycythemia vera, the approval was granted to Takeda Pharmaceuticals America, Inc. August 28 ... · Aug 31, 2026",
"title": "FDA Approves Mimrylo for Polycythemia Vera, Offering a ..."
},
{
"link": "https://www.instagram.com/p/Dc22pbhjZNv/",
"snippet": "Takeda wins FDA approval for Mimrylo (Rusfertide), first-in-class hepcidin mimetic for polycythemia vera, offering new option to control ... · 1 week ago",
"title": "The FDA has approved Takeda's Mimrylo (rusfertide) ..."
},
{
"link": "https://www.aabb.org/news-resources/news/article/2026/08/31/fda-approves-first-of-its-kind-drug-for-polycythemia-vera",
"snippet": "The Food and Drug Administration recently approved rusfertide (Mimrylo, Takeda) as a new treatment for adults with polycythemia vera · Aug 31, 2026",
"title": "FDA Approves First-of-its-Kind Drug for Polycythemia Vera"
},
{
"link": "https://www.ajmc.com/view/fda-approves-rusfertide-to-treat-erythrocytosis-in-polycythemia-vera",
"snippet": "FDA approves rusfertide, a first-in-class hepcidin-mimetic for polycythemia vera, cutting phlebotomies and improving hematocrit control and QOL. · Aug 29, 2026",
"title": "FDA Approves Rusfertide to Treat Erythrocytosis In ..."
},
{
"link": "https://www.drugs.com/newdrugs/fda-approves-mimrylo-rusfertide-polycythemia-vera-6872.html",
"snippet": "Mimrylo, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV) ...",
"title": "FDA Approves Mimrylo (rusfertide) for the Treatment of ..."
},
{
"link": "https://pvreporter.com/fda-approves-mimrylo-rusfertide-polycythemia-vera/",
"snippet": "Mimrylo approval at a glance ; FDA approval date, August 28, 2026 ; FDA-approved use, Treatment of erythrocytosis in adults with polycythemia vera. · Sep 1, 2026",
"title": "FDA Approves Mimrylo (Rusfertide) For Polycythemia Vera"
}
],
"success": true
},
"error": "",
"elapsed": 1.3996313599999999
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Camizestrant approval details and warnings",
"url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative"
},
"dispatch_id": "toolu_01MLUqrznC6TRs6E7JTjfEFb",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_01MLUqrznC6TRs6E7JTjfEFb",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Camizestrant approval details and warnings",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative"
}
},
"status": "running",
"updatedAt": 1789169304895
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_01MLUqrznC6TRs6E7JTjfEFb",
"status": "completed",
"result": {
"content": "FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - [Development & Approval Process | Drugs](/drugs/development-approval-process-drugs)\n - [Drug Approvals and Databases](/drugs/development-approval-process-drugs/drug-approvals-and-databases)\n - [Resources for Information | Approved Drugs](/drugs/drug-approvals-and-databases/resources-information-approved-drugs)\n - FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer\n\n\n - [Resources for Information | Approved Drugs](/drugs/drug-approvals-and-databases/resources-information-approved-drugs)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [Resources for Information | Approved Drugs](/drugs/drug-approvals-and-databases/resources-information-approved-drugs)\n\n\n\n\n - [Oncology (Cancer)/Hematologic Malignancies Approval Notifications](/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications)\n - [Ongoing | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals)\n - [Verified Clinical Benefit | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals)\n - [Withdrawn | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals)\n - [Other | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/other-cancer-accelerated-approvals)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Resources for Information | Approved Drugs](/drugs/drug-approvals-and-databases/resources-information-approved-drugs)\n\n\n\n\n - [Oncology (Cancer)/Hematologic Malignancies Approval Notifications](/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications)\n - [Ongoing | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals)\n - [Verified Clinical Benefit | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals)\n - [Withdrawn | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals)\n - [Other | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/other-cancer-accelerated-approvals)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOn September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (*ESR1)* mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.\n\nFDA also approved the Guardant360 CDx assay as a companion diagnostic device to identify patients with breast cancer with *ESR1* mutations for treatment with camizestrant.\n\nFull prescribing information for Etcamah will be posted on [Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm).\n\n## Efficacy and Safety\n\nEfficacy was evaluated in SERENA-6 (NCT04964934), a randomized, double-blind, placebo-controlled, multicenter trial to assess switching to camizestrant in combination with a CDK4/6 inhibitor versus continuing an aromatase inhibitor (AI) in combination with a CDK4/6 inhibitor in adult patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer with detectable *ESR1* mutations. The *ESR1* mutation status was assessed by blood circulating tumor deoxyribonucleic acid (ctDNA) testing using the Guardant360 CDx assay during first-line treatment with an AI and a CDK4/6 inhibitor. All patients were required to be currently receiving treatment of an AI in combination with a CDK4/6 inhibitor for ≥ 6 months as the initial endocrine based treatment with no evidence of disease progression as per investigator assessment. A total of 315 patients were randomized (1:1) to receive either camizestrant once daily in combination with a CDK4/6 inhibitor or AI (anastrozole or letrozole) orally once daily in combination with a CDK4/6 inhibitor.\n\nThe primary efficacy outcome measure was investigator-assessed progression-free survival (PFS) per RECIST v1.1. An additional efficacy outcome measure included overall survival (OS). Median PFS was 16 months (95% CI: 12.7, 18.2) in the camizestrant and CDK4/6 inhibitor arm and 9.2 months (95% CI: 7.2, 9.5) in the AI and CDK4/6 inhibitor arm (Hazard ratio 0.44 [95% CI: 0.31, 0.60]; p-value < 0.00001). At the time of the PFS analysis, OS data were not mature.\n\nThe prescribing information includes a boxed warning for the risk of arrhythmia due to QTc interval prolongation when concomitantly used with QTc interval prolonging drugs, as well as warnings and precautions for bradycardia and embryo-fetal toxicity.\n\n## Recommended Dosage\n\nThe recommended camizestrant dose is 75 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. Administer camizestrant in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib). Continue the CDK4/6 inhibitor at the same dosage as when the *ESR1* mutation was detected. Refer to the prescribing information of the CDK4/6 inhibitor for additional dosing information.\n\nCamizestrant in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) is being granted accelerated approval based on PFS measured from detection of *ESR1* mutation. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). For more information on ongoing accelerated approvals in oncology, refer to [Project Confirm](/about-fda/oncology-center-excellence/project-confirm).\n\nThis review was conducted under [Project Orbis](/about-fda/oncology-center-excellence/project-orbis), an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), the Brazilian Health Regulatory Agency (ANVISA), Health Canada, Singapore’s Health Sciences Authority (HSA), and Switzerland’s Swissmedic. The application reviews may be ongoing at the other regulatory agencies.\n\nThis application was discussed at an [Oncology Drugs Advisory Committee meeting](/advisory-committees/human-drug-advisory-committees/oncologic-drugs-advisory-committee). This review used the [Assessment Aid](/about-fda/oncology-center-excellence/assessment-aid), a voluntary submission from the applicant to facilitate the FDA’s assessment.\n\nThis application was granted standard review. Camizestrant received breakthrough therapy designation. A description of FDA expedited programs is in the [Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics](/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics).\n\nHealthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s [MedWatch Reporting System](https://www.accessdata.fda.gov/scripts/medwatch/index.cfm) or by calling 1-800-FDA-1088.\n\nFor assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s [Project Facilitate](/about-fda/oncology-center-excellence/project-facilitate) at 240-402-0004 or email [OncProjectFacilitate@fda.hhs.gov](mailto:OncProjectFacilitate@fda.hhs.gov).\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n09/04/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 12351,
"content_type": "text/html",
"description": "On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults....",
"status_code": 200,
"success": true,
"title": "FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer | FDA",
"url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative"
},
"error": "",
"elapsed": 0.059985672
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Zanvastro details and warnings",
"url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease"
},
"dispatch_id": "toolu_01SQzXkFC2X9Ga48NJBe8ENo",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_01SQzXkFC2X9Ga48NJBe8ENo",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Zanvastro details and warnings",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease"
}
},
"status": "running",
"updatedAt": 1789169304891
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_01SQzXkFC2X9Ga48NJBe8ENo",
"status": "completed",
"result": {
"content": "FDA Approves First Drug to Treat Alexander Disease | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [News & Events](/news-events)\n - [FDA Newsroom](/news-events/fda-newsroom)\n - [Press Announcements](/news-events/fda-newsroom/press-announcements)\n - FDA Approves First Drug to Treat Alexander Disease\n\n\n - [Press Announcements](/news-events/fda-newsroom/press-announcements)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [Press Announcements](/news-events/fda-newsroom/press-announcements)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFDA News Release\n\n\n\n# FDA Approves First Drug to Treat Alexander Disease\n\n\n\nNew therapy is the first to directly target the underlying cause of this rare neurological disease\n\n\n\n\n\n\n\n\n\n\n\n\n\n[** More Press Announcements](/news-events/newsroom/press-announcements)\n\n\n\n\n -\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n For Immediate Release: September 03, 2026\n\n\n\n\n\n\n\nThe U.S. Food and Drug Administration has approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients. Zanvastro is the first FDA-approved treatment for Alexander disease and the first therapy to directly target the protein buildup that drives the disease.\n\n“For patients with Alexander disease and their families, there have been no approved treatment options — only supportive care while the disease progresses,” **said Emily Freilich, M.D., Director of the Division of Neurology I in the FDA’s Center for Drug Evaluation and Research**. “Today’s approval is a landmark moment for this community, offering the first therapy that addresses the underlying cause of this rare and serious disease.”\n\nAlexander disease is a rare, progressive neurological disorder caused by mutations in the gene that produces glial fibrillary acidic protein (GFAP). When this protein is abnormal, it accumulates in the brain’s supportive cells, causing damage to the nervous system over time. The disease affects less than 1 in a million people and can cause a wide range of serious and potentially life-threatening problems, including seizures, loss of developmental milestones, difficulty walking, muscle weakness, and increased pressure in the brain.\n\nZanvastro is an antisense oligonucleotide — a type of medicine that works by reducing the production of the abnormal GFAP protein before it can accumulate and cause further damage. It is administered as an injection into the spinal canal every three months by a trained healthcare professional.\n\nThe efficacy and safety of Zanvastro were evaluated in a multicenter, randomized, controlled clinical study ([NCT04849741](https://clinicaltrials.gov/study/NCT04849741?term=%5BREDACTED%5D&viewType=%5BREDACTED%5D&rank=%5BREDACTED%5D)) enrolling 49 pediatric and adult patients with Alexander disease 2 years of age and older, and in an open-label substudy of 4 patients less than 2 years of age. Because Alexander disease is so rare and can affect patients across a wide range of ages, the FDA evaluated the available evidence in support of an indication covering patients from infancy through adulthood.\n\nIn patients aged 5 years and older who had measurable difficulties with walking at baseline, those treated with Zanvastro showed significantly better walking speed at 61 weeks compared to those who received no treatment. In children aged 2 to 4 years, where walking speed is not a reliable measure of progress, a broader assessment of motor skills — including standing, walking, running, and jumping — was used instead. Children treated with Zanvastro showed improvement on this measure while those in the control group declined.\n\nFor patients under 2 years of age, direct clinical trial data were limited by the rarity of the disease and lack of concurrent control. Pharmacokinetic modeling confirmed that drug levels in this age group are expected to be similar to those seen in older children at the same dose. This observation was also supported by safety data from four patients under 2 years of age treated in the study, as well as the safety data observed in the older pediatric patients. This approach supported extending the indication to the youngest patients while maintaining the evidentiary standards required to support approval.\n\nThe most common side effects of Zanvastro are vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. Patients and caregivers should inform their healthcare provider if symptoms consistent with meningitis develop, as aseptic meningitis has been reported in patients treated with Zanvastro. Patients and providers should carefully review the full prescribing information when making treatment decisions.\n\nZanvastro received [Orphan Drug](/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products), [Fast Track](/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track), [Breakthrough Therapy](/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy), and [Rare Pediatric Disease and Priority Review Voucher](/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs) designations, reflecting the serious and rare nature of Alexander disease, and FDA’s commitment to rare disease drug development.\n\nThe approval of Zanvastro for the treatment of Alexander disease was granted to Ionis Pharmaceuticals, Inc.\n\n---\n\n\n\n**Media:**\n[FDA Request for Comment](https://www.hhs.gov/request-for-comment-form/index.html?Agency=%5BREDACTED%5D)\n202-690-6343\n\n\n\n\n\n\n\n**Consumer:**\n888-INFO-FDA\n\n\n\n\n\n\n\n\n\n###\n\n\n\n\n\n\n\nBoilerplate\n\n\n\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.\n\n\n\n\n\n\n\n---\n\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n09/03/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n -\n\n\n\n## Follow FDA\n\n\n - [Follow @US_FDA on X](https://x.com/FDA)\n - [Follow FDA on Facebook](https://www.facebook.com/FDA)\n - [Follow @FDAMedia on X](https://x.com/FDAMedia)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 10383,
"content_type": "text/html",
"description": "The U.S. Food and Drug Administration has approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients.",
"status_code": 200,
"success": true,
"title": "FDA Approves First Drug to Treat Alexander Disease | FDA",
"url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease"
},
"error": "",
"elapsed": 0.056885927
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Mimrylo details and warnings",
"url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder"
},
"dispatch_id": "toolu_01VXLZJHSC886CsZpafqLmjD",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_01VXLZJHSC886CsZpafqLmjD",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Mimrylo details and warnings",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder"
}
},
"status": "running",
"updatedAt": 1789169304895
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_01VXLZJHSC886CsZpafqLmjD",
"status": "completed",
"result": {
"content": "FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [News & Events](/news-events)\n - [FDA Newsroom](/news-events/fda-newsroom)\n - [Press Announcements](/news-events/fda-newsroom/press-announcements)\n - FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder\n\n\n - [Press Announcements](/news-events/fda-newsroom/press-announcements)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [Press Announcements](/news-events/fda-newsroom/press-announcements)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFDA News Release\n\n\n\n# FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder\n\n\n\nFirst-in-class therapy targets the biology driving red blood cell overproduction in polycythemia vera\n\n\n\n\n\n\n\n\n\n\n\n\n\n[** More Press Announcements](/news-events/newsroom/press-announcements)\n\n\n\n\n -\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n For Immediate Release: August 28, 2026\n\n\n\n\n\n\n\nThe U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells. The excess cells can thicken the blood and increase the risk of cardiovascular issues, such as blood clots, stroke and heart attack.\n\nMimrylo offers a new treatment approach for patients whose disease has not been adequately controlled with existing therapies. It is the first approved treatment for polycythemia vera that mimics hepcidin, a hormone that naturally regulates iron in the body. By limiting the iron available to make new red blood cells, Mimrylo helps reduce their overproduction and keep red blood cell levels under control. This novel approach offers a new option for patients who have not achieved adequate control with existing therapies.\n\n“People living with polycythemia vera have long faced the challenge of managing a chronic blood disorder with frequent blood draws to help address the consequences of the red blood cell overproduction,” **said Tanya Wroblewski, M.D., Director of the Division of Nonmalignant Hematology within the FDA’s Center for Drug Evaluation and Research**. “Today's approval of Mimrylo offers a new, first-in-class option that has the potential to meaningfully reduce patient burden.\"\n\nA key goal of treatment for polycythemia vera is keeping the proportion of red blood cells in the blood (hematocrit) below 45% to reduce cardiovascular risks. This often requires phlebotomy, a procedure that removes blood from a vein to lower the number of red blood cells in the body. However, some patients continue to need frequent phlebotomies despite treatment, creating an ongoing burden.\n\nThe safety and efficacy of Mimrylo were evaluated in the [VERIFY](https://clinicaltrials.gov/study/NCT05210790?id=%5BREDACTED%5D&viewType=%5BREDACTED%5D&rank=%5BREDACTED%5D) trial, a multicenter, randomized, double-blind, placebo-controlled phase 3 study of 293 adults with polycythemia vera who required frequent phlebotomies despite ongoing standard-of-care therapy. Patients were randomized 1:1 to receive either Mimrylo or placebo over 32 weeks. Mimrylo treatment started at 19 mg, administered subcutaneously (under the skin) once weekly, and was titrated to maintain hematocrit levels below 45%.\n\nEfficacy was measured by the proportion of patients who did not meet criteria for phlebotomy between weeks 20 and 32 of the study. Overall, 76.9% of patients on Mimrylo required no phlebotomies during the 32-week period compared to 32.9% on placebo. The most common adverse reactions were injection site reactions and anemia.\n\nMimrylo received [priority review](/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review). The approval was granted to Takeda Pharmaceuticals America, Inc.\n\n\n\n###\n\n\n\n\n\n\n\nBoilerplate\n\n\n\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.\n\n\n\n\n\n\n\n---\n\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n08/28/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n -\n\n\n\n## Follow FDA\n\n\n - [Follow @US_FDA on X](https://x.com/FDA)\n - [Follow FDA on Facebook](https://www.facebook.com/FDA)\n - [Follow @FDAMedia on X](https://x.com/FDAMedia)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 8591,
"content_type": "text/html",
"description": "The U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells.",
"status_code": 200,
"success": true,
"title": "FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder | FDA",
"url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder"
},
"error": "",
"elapsed": 0.054949622
}{
"tool_name": "send_message",
"tool_input": {
"final": true,
"in_response_to": "6ead7f7e",
"message": "From FDA's human drugs news pages, Aug 28 to Sep 11, 2026. Four novel drugs (new molecular entities), plus two notable expansions of already-approved products.\n\n**Novel approvals**\n\n| Drug | Indication | Sponsor | Date | Key label limitations |\n|---|---|---|---|---|\n| Isembyld (apitegromab-mstn), IV | Spinal muscular atrophy in adults and children 2+ already on an SMN2-targeted treatment | Scholar Rock | 9/11/2026 | Add-on only, not monotherapy. Increased risk of fractures, including serious fractures. May cause fetal harm and may affect reproductive function. Efficacy shown mainly in ages 2-12 who could not walk independently. |\n| Etcamah (camizestrant), oral | HR+/HER2- locally advanced or metastatic breast cancer when an ESR1 mutation is detected during aromatase inhibitor plus CDK4/6 inhibitor therapy | AstraZeneca | 9/4/2026 | Accelerated approval, continued approval contingent on confirmatory trials. Boxed warning for QTc prolongation and arrhythmia with other QTc-prolonging drugs. Warnings for bradycardia and embryo-fetal toxicity. Requires an FDA-authorized test (Guardant360 CDx) and must be given with abemaciclib, palbociclib, or ribociclib. |\n| Zanvastro (zilganersen), intrathecal | Alexander disease in pediatric and adult patients | Ionis | 9/3/2026 | Aseptic meningitis reported, watch for meningitis symptoms. Given every 3 months by a trained professional. Under-2 indication rests on pharmacokinetic modeling plus 4 patients, not controlled data. Common: vomiting, back pain, cough, headache, post-lumbar puncture syndrome. |\n| Mimrylo (rusfertide), subcutaneous | Erythrocytosis in adults with polycythemia vera | Takeda Pharmaceuticals America | 8/28/2026 | Studied only in patients still needing frequent phlebotomy despite standard care. Weekly injection titrated to keep hematocrit under 45%. Common: injection site reactions and anemia. |\n\n**Expanded indications**\n- Joenja (leniolisib), 9/11/2026: first treatment for APDS in children 4-11 weighing at least 27 kg, weight-based dosing. Not for moderate-to-severe hepatic impairment. Pediatric clearance rests on an 8-patient open-label PK study.\n- Besremi (ropeginterferon alfa-2b-njft), 8/31/2026: adults with essential thrombocythemia. Titrated to 500 mcg every 2 weeks. Common: transaminase elevations, anemia, fever, bacterial infection, pruritus, weight loss.\n\nSources: [FDA Notable Approvals](https://www.fda.gov/drugs/news-events-human-drugs/notable-approvals-drugs) and [Novel Drug Approvals for 2026](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)."
},
"dispatch_id": "toolu_01QeD88dpQdxoNKokC1PdYMc",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": ""
}{
"tool_name": "send_message",
"dispatch_id": "toolu_01QeD88dpQdxoNKokC1PdYMc",
"status": "completed",
"result": "Delivered (confirmed) as 4 messages. Your draft was polished into texting register, so the wording differs from what you wrote; this is exactly what the user sees:\n1) Four novel drugs from FDA in the past two weeks, plus two expanded uses. All have notable limitations.\n2) ### Novel drug approvals, Aug 28–Sep 11, 2026\n\n| Drug | Indication | Sponsor | Date | Key label limitations |\n|---|---|---|---|---|\n| Isembyld (apitegromab-mstn), IV | Spinal muscular atrophy in adults and children 2+ already on an SMN2-targeted treatment | Scholar Rock | 9/11/2026 | Add-on only, not monotherapy. Increased risk of fractures, including serious fractures. May cause fetal harm and may affect reproductive function. Efficacy shown mainly in ages 2-12 who could not walk independently. |\n| Etcamah (camizestrant), oral | HR+/HER2- locally advanced or metastatic breast cancer when an ESR1 mutation is detected during aromatase inhibitor plus CDK4/6 inhibitor therapy | AstraZeneca | 9/4/2026 | Accelerated approval, continued approval contingent on confirmatory trials. Boxed warning for QTc prolongation and arrhythmia with other QTc-prolonging drugs. Warnings for bradycardia and embryo-fetal toxicity. Requires an FDA-authorized test (Guardant360 CDx) and must be given with abemaciclib, palbociclib, or ribociclib. |\n| Zanvastro (zilganersen), intrathecal | Alexander disease in pediatric and adult patients | Ionis | 9/3/2026 | Aseptic meningitis reported, watch for meningitis symptoms. Given every 3 months by a trained professional. Under-2 indication rests on pharmacokinetic modeling plus 4 patients, not controlled data. Common: vomiting, back pain, cough, headache, post-lumbar puncture syndrome. |\n| Mimrylo (rusfertide), subcutaneous | Erythrocytosis in adults with polycythemia vera | Takeda Pharmaceuticals America | 8/28/2026 | Studied only in patients still needing frequent phlebotomy despite standard care. Weekly injection titrated to keep hematocrit under 45%. Common: injection site reactions and anemia. |\n3) Leniolisib (Joenja) also expanded to children 4-11 on 9/11, and ropeginterferon alfa-2b (Besremi) to essential thrombocythemia on 8/31.\n4) https://www.fda.gov/drugs/news-events-human-drugs/notable-approvals-drugs\nhttps://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026\nThese are your words now, and this is the whole reply: the delivery layer chose its density and shape by design. Never dispute, re-explain, or apologize for the phrasing, and never send a supplement to restore detail it left out. Only a final send settles its request. Never chase wording with another send. If a fact in it is wrong and would change what the user does, correct it when their next message arrives.\n\nNothing else is open: no request awaits a reply and no work is running. A response with no tool call ends the run.\nanswers: 6ead7f7e-7bb0-44aa-9b12-22d72c7bd95e",
"error": "",
"elapsed": 7.746897092
}| Drug | Indication | Sponsor | Date | Key label limitations |
|---|---|---|---|---|
| Isembyld (apitegromab-mstn), IV | Spinal muscular atrophy in adults and children 2+ already on an SMN2-targeted treatment | Scholar Rock | 9/11/2026 | Add-on only, not monotherapy. Increased risk of fractures, including serious fractures. May cause fetal harm and may affect reproductive function. Efficacy shown mainly in ages 2-12 who could not walk independently. |
| Etcamah (camizestrant), oral | HR+/HER2- locally advanced or metastatic breast cancer when an ESR1 mutation is detected during aromatase inhibitor plus CDK4/6 inhibitor therapy | AstraZeneca | 9/4/2026 | Accelerated approval, continued approval contingent on confirmatory trials. Boxed warning for QTc prolongation and arrhythmia with other QTc-prolonging drugs. Warnings for bradycardia and embryo-fetal toxicity. Requires an FDA-authorized test (Guardant360 CDx) and must be given with abemaciclib, palbociclib, or ribociclib. |
| Zanvastro (zilganersen), intrathecal | Alexander disease in pediatric and adult patients | Ionis | 9/3/2026 | Aseptic meningitis reported, watch for meningitis symptoms. Given every 3 months by a trained professional. Under-2 indication rests on pharmacokinetic modeling plus 4 patients, not controlled data. Common: vomiting, back pain, cough, headache, post-lumbar puncture syndrome. |
| Mimrylo (rusfertide), subcutaneous | Erythrocytosis in adults with polycythemia vera | Takeda Pharmaceuticals America | 8/28/2026 | Studied only in patients still needing frequent phlebotomy despite standard care. Weekly injection titrated to keep hematocrit under 45%. Common: injection site reactions and anemia. |
### Novel drug approvals, Aug 28–Sep 11, 2026 | Drug | Indication | Sponsor | Date | Key label limitations | |---|---|---|---|---| | Isembyld (apitegromab-mstn), IV | Spinal muscular atrophy in adults and children 2+ already on an SMN2-targeted treatment | Scholar Rock | 9/11/2026 | Add-on only, not monotherapy. Increased risk of fractures, including serious fractures. May cause fetal harm and may affect reproductive function. Efficacy shown mainly in ages 2-12 who could not walk independently. | | Etcamah (camizestrant), oral | HR+/HER2- locally advanced or metastatic breast cancer when an ESR1 mutation is detected during aromatase inhibitor plus CDK4/6 inhibitor therapy | AstraZeneca | 9/4/2026 | Accelerated approval, continued approval contingent on confirmatory trials. Boxed warning for QTc prolongation and arrhythmia with other QTc-prolonging drugs. Warnings for bradycardia and embryo-fetal toxicity. Requires an FDA-authorized test (Guardant360 CDx) and must be given with abemaciclib, palbociclib, or ribociclib. | | Zanvastro (zilganersen), intrathecal | Alexander disease in pediatric and adult patients | Ionis | 9/3/2026 | Aseptic meningitis reported, watch for meningitis symptoms. Given every 3 months by a trained professional. Under-2 indication rests on pharmacokinetic modeling plus 4 patients, not controlled data. Common: vomiting, back pain, cough, headache, post-lumbar puncture syndrome. | | Mimrylo (rusfertide), subcutaneous | Erythrocytosis in adults with polycythemia vera | Takeda Pharmaceuticals America | 8/28/2026 | Studied only in patients still needing frequent phlebotomy despite standard care. Weekly injection titrated to keep hematocrit under 45%. Common: injection site reactions and anemia. |